Mechanisms of protection induced by attenuated Simian immunodeficiency virus II. Lymphocyte depletion does not abrogate protection

AIDS Research and Human Retroviruses

Volumn 14, Issue 13, 1998, Pages 1187-1198

  Stebbings, Richard ^a   Stott, Jim ^a   Almond, Neil ^a   Hull, Robin ^a   Lines, Jenny ^a   Silvera, Peter ^a   Sangster, Rebecca ^a   Corcoran, Terry ^a   Rose, Jane ^a   Cobbold, Steve ^b   Gotch, Frances ^c,d   McMichael, Andrew ^c   Walker, Barry ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DNA; GLYCOPROTEIN GP 140; PROTEIN P27; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNITY; LYMPHOCYTE; LYMPHOCYTE DEPLETION; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

EID: 0032169555     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.1187     Document Type: Article

References (79)

1. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, Hunt RD, Kanki PJ, Essex M, and Desrosiers RC: Isolation of a T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985; 228:1201-1203.
2. Letvin NL: Animal models for AIDS. Immunol Today 1990;11: 322-326.
3. Chakrabarti L, Guyader M, Alizon M, Daniel MD, Desrosiers RC, Tiollais P, and Sonigo P: Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature (London) 1987;328:543-547.
4. Franchini G, Gurgo G, Guo HG, Gallo RC, Collalti E, Fargnoli KA, Hall LF, Wong-Staal F, and Reitz MS: Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency virus. Nature (London) 1987;328:539-543.
5. Hirsch V, Riedel N, and Mullins JI: The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein. Cell 1987;49:307-319.
6. Desrosiers RC and Letvin NL: Animal models for acquired immunodeficiency syndrome. Rev Infect Dis 1987;9:439-446.
7. Gardner MB and Luciw PA: Animal models of AIDS. FASEB J 1989;3:2593-2606.
8. Lackner AA, Vogel P, Ramos RA, Kluge JD, and Marthas M: Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus. Am J Pathol 1994;145:428-439.
9. Baskin GB, Martin LN, Murphey-Corb M, Hu FS, Kuebler D, and Davison B: Distribution of SIV in lymph nodes of serially sacrificed rhesus monkeys. AIDS Res Hum Retroviruses 1995;11: 273-285.
10. Stott EJ, Chan WL, Mills KHG, Page M, Taffs F, Cranage M, Greenaway P, and Kitchin P: Preliminary report; protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected cell vaccine. Lancet 1990;336:1538-1541.
11. Cranage MP, Polyanskaya N, McBride B, Cook N, Ashworth LAE, Dennis M, Baskerville A, Greenaway PJ, Corcoran T, Kitchin P, Rose J, Murphey-Corb M, Desrosiers RC, Stott EJ, and Farrar GH: Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses 1993;9:13-22.
12. Goldstein S, Elkins WR, London WT, Hahn A, Goeken R, Martin JE, and Hirsch VM: Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells. J Med Primatol 1994;23:75-82.
13. mac251 challenge. AIDS Res Hum Retroviruses 1995;11:1397-1406.
14. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, and Desrosiers RC: Importance of the nef gene for maintenance of high viral loads and for the development of AIDS. Cell 1991;65:651-662.
15. Daniel MD, Kirchoff F, Czajak SC, Sehgal PK, and Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-1941.
16. Lohman BL, McChesney MB, Miller CJ, McGowan E, Joye SM, van Rompay KKA, Reay E, Antipa L, Pedersen NC, and Marthas ML: A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 1994;68:7021-7029.
17. Rud EW, Cranage M, Yon J, Quirk J, Ogilive L, Cook N, Webster S, Dennis M, and Clarke BE: Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol 1994; 75:529-543.
18. Almond N, Kent K, Cranage M, Rud E, Clarke B, and Stott EJ: Protection by attenuated immunodeficiency virus in macaques against challenge with-virus-infected cells. Lancet 1995;345: 1342-1344.
19. Stahl-Hennig C, Dittmer U, Nisslein T, Pekrun K, Petty H, Jurkiewicz E, Fuchs D, Wachter H, Rud EW, and Hunsmann G: Attenuated SIV imparts immunity to challenge with pathogenic spleen-derived SIV but cannot prevent repair of the nef deletion. Immunol Lett 1996;51:129-135.
20. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, and Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-1825.
21. Almond N, Rose J, Sangster R, Silvera P, Stebbings R, Walker B, and Stott EJ: Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J Gen Virol 1997;78:1919-1922.
22. Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MB: Virus-specific CD8+ cytotoxic T lymphocytes actively associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
23. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-4655.
24. Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, Ly TD, Goujard C, Guillet JG, and Gomard E: Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection. AIDS 1995;9:421-426.
25. Yasutomi Y, Reimann KA, Lord CI, Miller MD, and Letvin NL: Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J Virol 1993;67: 1707-1711.
26. Reimann KA, Tenner-Racz K, Racz P, Montefiori DC, Yasutomi Y, Ransil BJ, and Letvin NL: Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol 1994;68:2362-2370.
27. Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E, Silvera P, Dennis M, Corcoran T, Stott J, McMichael A, and Gotch F: Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Med 1995;1: 1167-1173.
28. Harrer E, Harrer T, Buchbinder S, Mann DL, Feinberg M, Yilma T, Johnson RP, and Walker BD: HIV-1-specific cytotoxic T lymphocyte responses in healthy, long-term nonprogressing seropositive persons. AIDS Res Hum Retroviruses 1994;10:S77-S78.
29. McElrath MJ, Corey L, and Greenberg PD: Cytotoxic T cells in adults and children. AIDS Res Hum Retroviruses 1994;10: S69-S72.
30. Ariyoshi K, Cham F, Berry N, Jaffar S, Sabally S, Corrah T, and Whittle H: HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load. AIDS 1995;9:555-559.
31. Bariou C, Genetet N, Ruffault A, Michelet C, Cartier F, and Genetet B: Longitudinal study of HIV-specific cytotoxic lymphocytes in HIV type 1-infected patients: Relative balance between host immune response and the spread of HIV type 1 infection. AIDS Res Hum Retroviruses 1997;13:1301-1312.
32. Ada GL: The immunological principles of vaccination. Lancet 1990;335:523-526.
33. Miller MD, Gould-Fogerite S, Shen L, Woods RM, Koenig S, Mannino RJ, and Letvin NL: Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes. J Exp Med 1992;176:1739-1744.
34. Kent SJ, Stallard V, Corey L, Hu SL, Morton WR, Gritz L, Panicali DL, and Greenberg PD: Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses. AIDS Res Hum Retroviruses 1994;10:551-560.
35. Hulskotte EG, Geretti AM, Siebelink KH, van-Amerongen G, Cranage MP, Rud EW, Norley SG, de-Vries P, and Osterhaus AD: Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). J Virol 1995;69: 6289-6296.
36. Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, and Robinson HL: Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 1996;70:3978-3991.
37. Johnson RP, Glickman RL, Yang JQ, Kaur A, Dion JT, Mulligan MJ, and Desrosiers RC: Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 1997;71:7711-7718.
38. Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, Leech S, Smith JD, Rud EW, Dennis MJ, and Hall GA: Macaques infected with live attenuated SIVmac are protected against super-infection via the rectal mucosa. Virology 1997;229:143-154.
39. Kadima-Nzuji M and Craighead JE: T-lymphocyte effect on murine cytomegalovirus pulmonary infection. Am J Pathol 1990;137: 907-912.
40. Castro BA, Homsy J, Lennette E, Murthy KK, Eichberg JW, and Levy JA: HIV-1 expression in chimpanzees can be activated by CD8+ cell depletion or CMV infection. Clin Immunol Immunopathol 1992;65:227-233.
41. Oldham G, Bridger JC, Howard CJ, and Parsons KR: In vivo role of lymphocyte subpopulations in the control of virus excretion and mucosal antibody responses of cattle infected with rotavirus. J Virol 1993;67:5012-5019.
42. Thomas LH, Cook RS, Howard CJ, Gaddum RM, and Taylor G: Influence of selective T-lymphocyte depletion on the lung pathology of gnotobiotic calves and the distribution of different T-lymphocyte subsets following challenge with bovine respiratory syncytial viru. Res Vet Sci 1996;61:38-44.
43. Hasenkrug KJ and Chesebro B: Immunity to retroviral infection: The Friend virus model. Proc Natl Acad Sci USA 1997;94: 7811-7816.
44. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
45. Almond N, Jenkins A, Slade A, Heath A, Cranage M, and Kitchin P: Population sequence analysis of a simian immunodeficiency virus (32H reisolate of SIVmac251): A virus stock used for international vaccine studies. AIDS Res Hum Retroviruses 1992; 8:77-88.
46. Waldmann H: Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol 1989;7:407-444.
47. Riechmann L, Clark M, Waldmann H, and Winter G: Reshaping human antibodies for therapy. Nature (London) 1988;332:323-327.
48. Hale G, Xia MQ, Tighe HP, Dyer MJ, and Waldmann H: The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118-127.
49. Rose J, Silvera P, Flanagan B, Kitchin P, and Almond N: The development of PCR based assays for the detection and differentiation of simian immunodeficiency virus in vivo. J Virol Methods 1995;51:229-240.
50. Silvera P, Flanagan B, Kent K, Rud E, Powell C, Corocran T, Bruck C, Thiriart C, Haigwood NL, and Stott EJ: Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques. AIDS Res Hum Retroviruses 1994;10:1295-1304.
51. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, and Waldmann H: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-752.
52. Cohen J: Novel campaign to test live HIV vaccine. Science 1997;277:1035.
53. Embretson E, Zupancic M, Ribas JJ, Burke A, Racz P, Tenner-Racz K, and Hasse AT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (London) 1993;362:359-362.
54. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, and Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 1993;362:355-335.
55. Chakrabarti L, Isola P, Cumont MC, Claessens-Maire MA, Hurtrel M, Montagnier L, and Hurtrel B: Early stages of simian immunodeficiency virus infection in lymph nodes: Evidence for high viral load and successive populations of target cells. Am J Pathol 1994;144:1226-1237.
56. Matano T, Shibata R, Siemon C, Connors M, Lane HC, and Martin MA: Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998;72:164-169.
57. Ghobrial RRM, Boublik M, Winn HJ, and Auchincloss H Jr: In vivo use of monoclonal antibodies against murine T cell antigens. Clin Immunol Immunopathol 1989;52:486-506.
58. Xia MQ, Hale G, Lifely MR, Ferguson MAJ, Campbell D, Packman L, and Waldmann H: Structure of the Campath-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993; 293:633-640.
59. Brett S, Baxter G, Cooper H, Johnston JM, Tite J, and Rapson N: Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996;88:13-19.
60. Kai O and Franklin RM: Effects of cyclosporin A in mouse lymphoid tissues. Br J Exp Pathol 1983;64:534-541.
61. Xiao-Ning X, Screaton GR, Gotch FM, Dong T, Tan R, Almond N, Walker W, Stebbings R, Kent K, Shigekazu N, Stott EJ, and McMichael AJ: Evasion of cytotoxic T lymphocyte (CTL) responses by nef-independent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med 1997;186:7-16.
62. Rud EW, Vogel T, Sherring A, Bogdanovic D, Ko D, Brown J, Kim J, Cranage MP, and Parenteau M: Virological and immunological parameters in cynomolgus macaques infected with pathogenic or attenuated SIV: Correlations with the outcome of a challenge with SHIV or SIVSMM(PBJ14)? 2nd European Conference on Experimental AIDS Research. Stockholm, Sweden, 1997, Abstr. 47-W4.
63. Vogel T, Sherring A, Bogdanovic D, Ko D, Brown J, Kim J, Cranage MP, Parenteau M, Beausoleil N, Fournier J, and Rud EW: CTL-response in cynomolgus macaques infected with pathogenic or attenuated SIV: Correlations with the outcome of a challange with SHIV? 2nd European Conference on Experimental AIDS Research. Stockholm, Sweden, 1997, Abstr. 48-W4.
64. Kent KA, Kitchin P, Mills KH, Page M, Taffs F, Corcoran T, Silvera P, Flanagan B, Powell C, Rose J, Ling C, Aubertin A-M, and Stott EJ: Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing antibodies failed to protect against challenge with SIVmac251. AIDS Res Hum Retroviruses 1994;10:189-194.
65. Gardner M, Rosental A, Jennings M, Yee J, Antipa L, and Robinson E Jr: Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res Hum Retroviruses 1995;11: 843-853.
66. Stott EJ, Almond N, West W, Kent K, Cranage M, and Rud E: Protection against simian immunodeficiency virus infection of macaques by cellular or viral antigens. In Neuvieme Colloque des Cent Gardes (Girard M, ed.). Fondation Merieux, Lyon, France 1994, pp. 219-224.
67. Haigwood NL, Watson A, Sutton WF, McClure J, Lewis A, Ranchalis J, Travis B, Voss G, Letvin NL, Hu S-L, Hirsch VM, and Johnson PR: Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile. Immunol Lett 1996;51:107-114.
68. Ada G: Do cytotoxic T lymphocytes clear some HIV/SIV infections? J Med Primatol 1996;25:158-162.
69. Walker CM, Moody DJ, Stites DP, and Levy JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-1566.
70. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC and Lusso P: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
71. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM, and Koup RA: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nature Med 1996;2:412-417.
72. Mitchell T and Risser R: Interference established in mice by infection with Friend murine leukemia virus. J Virol 1992;66: 5696-5702.
73. Corbin A and Sitbon M: Protection against retroviral disease after vaccination is conferred by interference to superinfection with attenuated murine leukemia viruses. J Virol 1993;67:5146-5142.
74. Willerford DM, Gale MJ, Benveniste RE, Clark EA, and Gallatin WM: Simian immunodeficiency virus is restricted to a subset of blood CD4+ lymphocytes that includes memory cells. J Immunol 1990;144:3779-3783.
75. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, and Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-673.
76. Loetscher P, Seitz M, Baggiolini M, and Moser B: Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996;184:569-577.
77. Hyjek E, Lischner HW, Hyslop T, Bartkowiak J, Kubin M, Trinchieri G, and Kozbor D: Cytokine patterns during progression to AIDS in children with perinatal HIV infection. J Immunol 1995;155:4060-4071.
78. Meroni L, Trabattoni D, Balotta C, Riva C, Gori A, Moroni M, Villa ML, Clerici M, and Galli M: Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. AIDS 1996;10:23-30.
79. Stebbings RJ, Lines JL, Almond NM, Stott EJ, and Walker KB: Cytokine profiling of simian immunodeficiency virus infection of cynomologus macaques. Pathogenic SIVmac251 pJ5C versus nonpathogenic attenuated SIVmac251 pC8C reveals divergence. Biochem Soc Trans 1997;25:285S.